524731 — Jenburkt Pharmaceuticals Cashflow Statement
0.000.00%
- IN₹5.89bn
- IN₹5.68bn
- IN₹1.52bn
- 76
- 27
- 81
- 69
Annual cashflow statement for Jenburkt Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | IAS | IAS | IAS | IAS | — |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 165 | 223 | 246 | 260 | 321 |
Depreciation | |||||
Non-Cash Items | 15.2 | 34.3 | 44.6 | 62.9 | 60.6 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -6 | -182 | -143 | -265 | -129 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | 195 | 94 | 171 | 81.2 | 279 |
Capital Expenditures | -11.5 | -30.5 | -21 | -25.5 | -197 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -176 | 17.2 | 47.2 | 19.7 | 26.7 |
Sale of Fixed Assets | |||||
Change in Net Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -188 | -13.3 | 26.2 | -5.8 | -170 |
Financing Cash Flow Items | -2.04 | -3.41 | -5.17 | -2.5 | -2.8 |
Other Financing Cash Flow | |||||
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -7.14 | -55.3 | -210 | -70.8 | -76.2 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -0.403 | 25.4 | -13.7 | 4.66 | 32.4 |